Group 1 - The core viewpoint of the article highlights the financial performance of Kangtuo Medical in Q3 2025, showing a revenue increase and a positive net profit [1] - Kangtuo Medical reported a revenue of approximately 251 million yuan for the first three quarters of 2025, representing a year-on-year increase of 4.57% [1] - The net profit attributable to shareholders of the listed company was approximately 76.72 million yuan [1] Group 2 - As of the report date, Kangtuo Medical has a market capitalization of 2.9 billion yuan [2]

证券代码：688314 证券简称：康拓医疗 公告编号：2025-040 西安康拓医疗技术股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 04 日（星期二）14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 28 日（星期二）至 11 月 03 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥80,772,405.35, a decrease of 6.92% compared to the same period last year[4] - The total profit for the period was ¥24,365,076.68, reflecting a decline of 26.31% year-on-year[4] - The net profit attributable to shareholders was ¥21,716,516.65, down 22.22% from the previous year[4] - Total operating revenue for the first three quarters of 2025 reached ¥251,088,755.11, an increase of 4.1% compared to ¥240,117,907.83 in the same period of 2024[19] - Total operating costs for the first three quarters of 2025 were ¥156,565,067.29, up from ¥148,313,124.73 in 2024, reflecting a year-over-year increase of 5.5%[19] - Net profit for the first three quarters of 2025 was ¥75,906,135.43, slightly down from ¥76,006,339.62 in 2024, indicating a decrease of 0.1%[20] - The company reported a total profit of ¥89,724,401.40 for the first three quarters of 2025, compared to ¥92,332,439.71 in 2024, reflecting a decrease of 2.8%[20] Research and Development - Research and development expenses totaled ¥10,114,843.75, an increase of 23.61% compared to the same quarter last year, representing 12.52% of operating revenue[5] - Research and development expenses for the first three quarters of 2025 were ¥17,980,206.24, up from ¥16,399,769.03 in 2024, representing an increase of 9.7%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥790,933,245.95, an increase of 5.85% from the end of the previous year[5] - The equity attributable to shareholders increased by 8.29% year-on-year, reaching ¥688,268,864.98[5] - The company's total liabilities decreased to ¥100,587,268.91 in 2025 from ¥109,374,780.75 in 2024, a reduction of approximately 8.1%[17] - The total equity attributable to shareholders increased to ¥688,268,864.98 in 2025, compared to ¥635,577,490.21 in 2024, marking an increase of about 8.3%[17] Cash Flow - The net cash flow from operating activities was ¥23,893,689.92, down 29.17% year-on-year[5] - The company’s cash flow from operating activities for the first three quarters of 2025 showed a positive trend, although specific figures were not disclosed in the provided data[21] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 287,099,764.83, a slight decrease of 0.65% compared to CNY 288,963,805.42 in the same period of 2024[22] - The net cash flow from operating activities decreased to CNY 86,083,545.57, down 21.5% from CNY 109,654,732.43 year-on-year[22] - Cash inflow from investment activities totaled CNY 629,164,479.21, significantly increasing by 81.1% from CNY 347,020,186.10 in the previous year[23] - The net cash flow from investment activities was negative at CNY -193,046,531.01, worsening from CNY -151,796,237.78 in the same period last year[23] - Cash outflow from financing activities was CNY 33,577,694.13, compared to CNY 29,942,653.10 in the previous year, reflecting an increase of 8.7%[23] - The ending balance of cash and cash equivalents decreased to CNY 237,174,086.51, down 21.6% from CNY 302,407,498.71 at the end of the same period last year[23] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 5,879[11] - The largest shareholder, Hu Liren, holds 39,545,788 shares, representing 48.68% of total shares[11] Current Assets - Total current assets as of September 30, 2025, amount to ¥422,128,968.67, slightly up from ¥418,250,595.94 at the end of 2024[15] - Cash and cash equivalents decreased to ¥237,963,156.13 from ¥378,532,413.99[15] - Accounts receivable increased to ¥8,893,422.12 from ¥5,916,765.08, indicating a growth of 50.5%[15] - Inventory increased to ¥30,934,238.91 from ¥24,750,588.76, reflecting a rise of 24.9%[15] - Non-current assets total ¥368,804,277.28, up from ¥328,972,266.97[16] - Total assets increased to ¥790,933,245.95 from ¥747,222,862.91[16] - Current liabilities include accounts payable of ¥26,140,856.99, slightly up from ¥25,845,698.39[16] - The company has no short-term borrowings reported as of September 30, 2025[16] Other Information - The company reported a total of ¥195,239.57 in government subsidies recognized during the period, contributing positively to the financial results[7] - The company has not disclosed any significant new product developments or market expansion strategies in this report[10] - The company has not reported any net profit from mergers under common control for the current or previous periods, indicating no impact from such activities on the financial results[21] - The company experienced a negative impact of CNY -28,578.29 from exchange rate fluctuations on cash and cash equivalents[23]

Core Viewpoint - Kangtuo Medical announced a cash dividend of 0.20 yuan per share (including tax) for the first half of 2025, with key dates for the dividend distribution outlined [1] Summary by Categories Dividend Announcement - The cash dividend of 0.20 yuan per share will be distributed to shareholders [1] - The record date for the dividend is set for October 10, 2025 [1] - The ex-dividend date and the date of cash dividend payment are both scheduled for October 13, 2025 [1]

证券代码：688314 证券简称：康拓医疗 公告编号：2025-038 西安康拓医疗技术股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.20元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/10/10 | 2025/10/13 | 2025/10/13 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 9 月 16 日的2025年第二次临时股东会审议通 过。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本81,239,172股为基数，每股派发现金 红利0.20元（含税），共计派发现金红利16,247,834.40元。 三、 相关 ...

Group 1: Changshan Pharmaceutical - The company is preparing for clinical trials of Aibennate peptide for weight loss, with no current plans for oral formulation development [1] - Aibennate peptide is a long-acting GLP-1 receptor agonist, developed through chemical modification of exenatide [1] - The marketing preparation includes team building, product knowledge training, and marketing strategy formulation [1] Group 2: Fosun Pharma - Four innovative drugs approved in the first half of the year are expected to gradually increase sales in the coming months [2] - Innovative drug revenue exceeded 4.3 billion yuan, a year-on-year increase of 14.26%, accounting for over 30% of total drug revenue [2] - The company is actively participating in negotiations for the inclusion of its innovative drugs in insurance and national basic medical insurance directories [2] Group 3: Tiantan Biological Products - The company has established an international cooperation department to enhance its global market presence [3] - Products such as tetanus immunoglobulin and rabies immunoglobulin have already been exported [3] - The company is focused on international certification and registration of key products [3] Group 4: Kangtuo Medical - The US-based subsidiary BIOPLATE has launched a local production line for PEEK plates [4] - The company has completed market access in nearly 40 countries and regions [4] - The marketing of "4D bioactive plates" and PEEK fixation systems is underway in the US [4] Group 5: Tailong Pharmaceutical - The company is focusing on the development of modified new drugs across various therapeutic areas including respiratory, digestive, and oncology [5] - Projects in progress include treatments for Alzheimer's disease and schizophrenia [5] Group 6: Heng Rui Pharmaceutical - The HRS-5635 injection has been included in the list of proposed breakthrough therapies [6][7] - Chronic hepatitis B infection affects approximately 257 million people globally, with a significant mortality rate [7] - There is a pressing need for more effective treatments to achieve functional cure for chronic hepatitis B [7]

Group 1 - The core viewpoint of the news is that 康拓医疗 is actively expanding its global presence through its subsidiary BIOPLATE, which is focused on enhancing profitability and market access in various countries [1] - BIOPLATE has significantly reduced its losses in the first half of 2025 compared to the same period last year by improving operational efficiency and diversifying its product line [1] - The company has achieved product market access in nearly 40 countries or regions and plans to expand its team and resources to grow its business scale [1] Group 2 - The PEEK bone plate production line in the United States has officially commenced operations, and the company is actively promoting its products in the market [1] - The management addressed concerns regarding the slight decline in gross margin by implementing aggressive marketing strategies and optimizing production processes to stabilize margins [1] - In the new business areas of oral, thoracic surgery, and maxillofacial repair, the company is expanding its "优贝雅" brand implant system and has acquired equity in 蝾螈生物 to enhance its product offerings in the oral implant market [2]

Group 1 - The core point of the announcement is the resolution of the second extraordinary general meeting of shareholders held by Xi'an Kangtuo Medical Technology Co., Ltd. on September 16, 2025, with no rejected proposals [1][2]. - The meeting was convened by the board of directors and chaired by Chairman Hu Liren, utilizing a combination of on-site and online voting methods, in compliance with the Company Law of the People's Republic of China and the company's articles of association [2][3]. - A total of 9 directors were in office, with 7 attending the meeting, including 4 participating via communication methods, and the board secretary and financial director also attended [3]. Group 2 - Two ordinary resolution proposals were reviewed and approved: the profit distribution plan for the first half of 2025 and the proposal to provide financial assistance to affiliated companies [4][5]. - Both proposals received more than half of the voting rights held by shareholders or their proxies present at the meeting, with separate counting for minority investors [5]. - The meeting was witnessed by lawyers from Guohao Law Firm (Xi'an), who confirmed that the convening and proceedings of the meeting complied with relevant laws and regulations [5].

证券代码：688314 证券简称：康拓医疗 公告编号：2025-037 西安康拓医疗技术股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 9 月 16 日 （二） 股东会召开的地点：西安市高新区毕原一路西段 1451 号西安康拓医 疗技术股份有限公司三楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股 东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 52 | | --- | --- | | 普通股股东人数 | 52 | | 2、出席会议的股东所持有的表决权数量 | 52,923,358 | | 普通股股东所持有表决权数量 | 52,923,358 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 65.1451 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 65.1451 ...

国浩律师（西安）事务所 法律意见书 国浩律师（西安）事务所 关于西安康拓医疗技术股份有限公司 2025年第二次临时股东会的 法律意见书 致：西安康拓医疗技术股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）《中华人民共和 国公司法》（以下简称"《公司法》"）等法律、行政法规和规范性文件的规定， 国浩律师（西安）事务所（以下简称"国浩"）接受西安康拓医疗技术股份有限公 司（以下简称"公司"）的委托，指派律师出席公司 2025 年第二次临时股东会（以 下简称"本次股东会"）并对本次股东会的相关事项进行见证，依法出具本法律意 见书。 国浩及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》和 《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经发生 或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了 充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发表的结论 性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律 责任。 本法律意见书仅供公司 2025 年第二次临时股东会之目的使用，本所及经办律师 同意本法律意见书随同 ...